A single arm, single-dose, safety and pharmacokinetic study of ReliBeta (Interferon beta-1a 2x30 micrograms pre-filled syringe) from Reliance Life Sciences Pvt. Ltd., India in normal, healthy, adult, human subjects under fasting conditions
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Reliance Life Sciences
Most Recent Events
- 25 Jun 2018 New trial record